SequelSEC

OptimizeRx Corp OPRX

Services-Business Services, NEC · CIK 0001448431 · Fiscal year ends 1231

Revenue
$109.43M
Fiscal year ended 2025-12-31
Operating income
$11.69M
Fiscal year ended 2025-12-31
Free cash flow
$18.66M
Fiscal year ended 2025-12-31

OptimizeRx Corp (OPRX) reported revenue of $109.43M and net income of $5.13M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from OptimizeRx Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Business Services, NEC.

Income

OptimizeRx Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$109.43M$92.13M$71.52M$62.45M$61.29M$43.31M$24.60M$21.21M$12.13M$7.75M
Cost of revenue$35.83M$32.75M$28.62M$23.48M$25.65M$19.21M$9.16M$9.00MUnavailableUnavailable
Gross profit$73.60M$59.38M$42.90M$38.97M$35.64M$24.11M$15.44M$12.21M$5.95M$4.34M
Operating income$11.69M-$13.71M-$26.40M-$12.29M$361.10K-$2.14M-$3.69M$180.13K-$2.13M-$1.58M
Net income$5.13M-$20.11M-$17.57M-$11.44M$378.08K-$2.21M-$3.14M$226.34K-$2.10M-$1.54M
Research & development$0$0UnavailableUnavailableUnavailable$0$1.60M$0UnavailableUnavailable
Weighted-average diluted sharesshares 19.00Mshares 18.29Mshares 17.12Mshares 17.78Mshares 17.69Mshares 14.83Mshares 13.39Mshares 11.86Mshares 9.82MUnavailable
Pretax income$6.95M-$19.38M-$25.16M-$11.44M$378.08K-$2.21M-$4.04M$226.34K-$2.10M-$1.54M
Income tax expense$1.82M$725.00K-$7.60MUnavailableUnavailableUnavailable-$897.96KUnavailableUnavailableUnavailable
Diluted EPS$0.27$-1.10$-1.03$-0.64$0.02$-0.15$-0.23$0.02$-0.21Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailable$33.49M$27.70MUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

OptimizeRx Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$23.36M$13.38M$13.85M$18.21M$84.68M$10.52M$18.85M$8.91M$5.12M$7.03M
Total assets$176.92M$171.17M$183.37M$134.65M$140.99M$60.33M$56.64M$25.05M$9.76M$11.48M
Current assets$64.72M$53.97M$54.33M$98.58M$115.11M$32.86M$27.14M$15.73M$8.81M$10.18M
Total liabilities$48.62M$54.17M$56.82M$8.54M$9.61M$10.35M$11.78M$6.60M$3.54MUnavailable
Current liabilities$21.26M$18.65M$17.88M$8.40M$9.37M$10.03M$6.11M$4.23M$3.54M$3.67M
Total equity incl. NCI$128.29M$117.00M$126.55M$126.11M$131.38M$49.97M$44.86M$18.46M$6.22M$7.81M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$37.75M$38.21M$36.25M$22.16M$24.80M$17.89M$7.42M$6.46M$3.43M$1.95M
Goodwill$70.87M$70.87M$78.36M$22.67M$14.74M$14.74M$14.74M$3.68MUnavailableUnavailable
Long-term debt$21.42M$30.82M$34.23MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

OptimizeRx Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$18.72M$4.89M-$7.24M$10.65M$726.04K-$6.31M-$1.66M$792.56K-$1.48M-$465.96K
Capital expenditures$58.00K$112.00K$87.00K$81.00K$100.32K$68.04K$87.72K$34.36K$42.24K$178.43K
Investing cash flow$68.00K-$450.00K-$25.34M-$58.18M-$486.00K-$124.72K-$10.58M-$5.69M-$42.24K-$349.54K
Financing cash flow-$8.80M-$4.91M$28.22M-$18.95M$73.92M-$1.90M$22.18M$8.69M-$390.00K-$357.42K
Net change in cash$9.98M-$472.00K-$4.36M-$66.47M$74.16M-$8.34M$9.94M$3.79M-$1.91M-$1.17M
Stock-based compensation$6.96M$11.47M$13.72M$15.75M$5.49M$3.17M$2.26M$2.52M$87.38K$175.18K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$7.52M$20.02MUnavailableUnavailableUnavailableUnavailable$390.00K$806.92K
Depreciation & amortization$4.33M$4.33M$2.40M$2.02M$1.97M$2.08M$1.28M$316.50K$324.55K$235.28K

Derived

OptimizeRx Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$18.66M$4.78M-$7.33M$10.57M$625.72K-$6.38M-$1.75M$758.19K-$1.52M-$644.40K
Gross margin67.3%64.5%60.0%62.4%58.1%55.7%62.8%57.6%49.1%56.0%
Operating margin10.7%-14.9%-36.9%-19.7%0.6%-4.9%-15.0%0.8%-17.6%-20.4%
FCF margin17.0%5.2%-10.2%16.9%1.0%-14.7%-7.1%3.6%-12.6%-8.3%
SBC / revenue6.4%12.4%19.2%25.2%9.0%Unavailable9.2%11.9%0.7%2.3%
Current ratio3.04x2.89x3.04x11.74x12.29x3.28x4.44x3.72x2.49x2.78x
Revenue YoY growth18.8%28.8%14.5%1.9%41.5%76.1%16.0%74.9%56.5%Unavailable
Net margin4.7%-21.8%-24.6%-18.3%0.6%-5.1%-12.8%1.1%-17.3%-19.9%
R&D / revenue0.0%0.0%UnavailableUnavailableUnavailableUnavailable6.5%0.0%UnavailableUnavailable
CapEx / revenue0.1%0.1%0.1%0.1%0.2%0.2%0.4%0.2%0.3%2.3%
Long-term debt / equity0.17xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate26.2%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OPRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.